Neonatal Fc receptor and IgG-based therapeutics

mAbs

Volumn 3, Issue 5, 2011, Pages 422-430

  Kuo, Timothy T ^a   Aveson, Victoria G ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Albumin; Antibody; Brambell receptor; Fab; Fc fusion; Fcgrt; FcRn; IgG; Transcytosis

Indexed keywords

ABDEGS ANTIBODY; ADALIMUMAB; BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2 IMMUNOGLOBULIN G1 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERYTHROPOIETIN; ETARACIZUMAB; FC RECEPTOR; FOLLITROPIN; HYBRID PROTEIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2 ANTIBODY; INFLIXIMAB; MACROGOL; MOTAVIZUMAB; PEPTIDE; PEPTIDE SYN1436; RECOMBINANT ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 9; RITUXIMAB; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA IMMUNOGLOBULIN G1 ANTIBODY; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH FACTOR IMMUNOGLOBULIN G1 ANTIBODY; VASCULOTROPIN ANTIBODY;

ADAPTIVE IMMUNITY; AUTOIMMUNE DISEASE; BINDING AFFINITY; BRAIN; BREAST; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; DRUG HALF LIFE; EYE; GENE MUTATION; GENITAL SYSTEM; GUILLAIN BARRE SYNDROME; HEMATOPOIETIC CELL; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DEFICIENCY; IMMUNIZATION; INTESTINE; KIDNEY; LIVER; LIVESTOCK; LUNG; MUCOCUTANEOUS LYMPH NODE SYNDROME; NONHUMAN; PASSIVE IMMUNIZATION; PLACENTA; PLASMA HALF LIFE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SKIN; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIBODY AFFINITY; AUTOIMMUNE DISEASES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; MICE; MODELS, MOLECULAR; RABBITS; RECEPTORS, FC;

EID: 80052598705     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.3.5.16983     Document Type: Review

References (80)

1. Good R.A., Lorenz E. Historic aspects of intravenous immunoglobulin therapy. Cancer 1991; 68:1415-1421
2. Simister N.E., Mostov K.E. An Fc receptor structurally related to MHC class I antigens. Nature 1989; 337:184-187 (Pubitemid 19025381)
3. Kuo T.T., De Muinck E.J., Claypool S.M., Yoshida M., Nagaishi T., Aveson V.G., et al. N-Glycan Moieties in Neonatal Fc Receptor Determine Steady-state Membrane Distribution and Directional Transport of IgG. J Biol Chem 2009; 284:8292-8300
4. Tzaban S., Massol R.H., Yen E., Hamman W., Frank S.R., Lapierre L.A., et al. The recycling and transcytotic pathways for IgG transport by FcRn are distinct and display an inherent polarity. J Cell Biol 2009; 185:673-684
5. Qiao S.W., Kobayashi K., Johansen F.E., Sollid L.M., Andersen J.T., Milford E., et al. Dependence of antibody-mediated presentation of antigen on FcRn. Proc Natl Acad Sci USA 2008; 105:9337-9342
6. + dendritic cells. PNAS 2011; In press.
7. Kuo T.T., Baker K., Yoshida M., Qiao S.W., Aveson V.G., Lencer W.I., et al. Neonatal Fc receptor: From immunity to therapeutics. J Clin Immunol 2010; 30:777-789
8. Baker K., Qiao S.W., Kuo T., Kobayashi K., Yoshida M., Lencer W.I., et al. Immune and non-immune functions of the (not so) neonatal Fc receptor, FcRn. Semin Immunopathol 2009; 31:223-236
9. Roopenian D.C., Akilesh S. FcRn: The neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7:715-725 (Pubitemid 47327396)
10. Raghavan M., Gastinel L.N., Bjorkman P.J. The class I major histocompatibility complex related Fc receptor shows pH-dependent stability differences correlating with immunoglobulin binding and release. Biochemistry 1993; 32:8654-8660 (Pubitemid 23270453)
11. Huber A.H., Kelley R.F., Gastinel L.N., Bjorkman P.J. Crystallization and stoichiometry of binding of a complex between a rat intestinal Fc receptor and Fc. J Mol Biol 1993; 230:1077-1083 (Pubitemid 23159945)
12. Raghavan M., Chen M.Y., Gastinel L.N., Bjorkman P.J. Investigation of the interaction between the class I MHC-related Fc receptor and its immunoglobulin G ligand. Immunity 1994; 1:303-315
13. Kim J.K., Firan M., Radu C.G., Kim C.H., Ghetie V., Ward E.S. Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn. Eur J Immunol 1999; 29:2819-2825 (Pubitemid 30099006)
14. Medesan C., Matesoi D., Radu C., Ghetie V., Ward E.S. Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1. J Immunol 1997; 158:2211-2217 (Pubitemid 127470004)
15. Schultze H.E., Heremans J.F. Molecular biology of human proteins: with special reference to plasma proteins. Nature and Metabolism of Extracellular Proteins. New York: Elsevier 1966.
16. Chaudhury C., Mehnaz S., Robinson J.M., Hayton W.L., Pearl D.K., Roopenian D.C., et al. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med 2003; 197:315-322 (Pubitemid 36184238)
17. Andersen J.T., Dee Qian J., Sandlie I. The conserved histidine 166 residue of the human neonatal Fc receptor heavy chain is critical for the pH-dependent binding to albumin. Eur J Immunol 2006; 36:3044-3051 (Pubitemid 44782576)
18. Kenanova V.E., Olafsen T., Salazar F.B., Williams L.E., Knowles S., Wu A.M. Tuning the serum persistence of human serum albumin domain III:Diabody fusion proteins. Protein Eng Des Sel 2010; 23:789-798
19. Pollastrini J., Dillon T.M., Bondarenko P., Chou R.Y. Field flow fractionation for assessing neonatal Fc receptor and Fcgamma receptor binding to monoclonal antibodies in solution. Anal Biochem 414:88-98.
20. Ober R.J., Radu C.G., Ghetie V., Ward E.S. Differences in promiscuity for antibody-FcRn interactions across species: Implications for therapeutic antibodies. Int Immunol 2001; 13:1551-1559 (Pubitemid 33133882)
21. Zhou J., Johnson J.E., Ghetie V., Ober R.J., Ward E.S. Generation of mutated variants of the human form of the MHC class I-related receptor, FcRn, with increased affinity for mouse immunoglobulin G. J Mol Biol 2003; 332:901-913 (Pubitemid 37101376)
22. Andersen J.T., Daba M.B., Berntzen G., Michaelsen T.E., Sandlie I. Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding. J Biol Chem 2010; 285:4826-4836
23. Ober R.J., Martinez C., Lai X., Zhou J., Ward E.S. Exocytosis of IgG as mediated by the receptor, FcRn: An analysis at the single-molecule level. Proc Natl Acad Sci USA 2004; 101:11076-11081 (Pubitemid 38989586)
24. Yoshida M., Claypool S.M., Wagner J.S., Mizoguchi E., Mizoguchi A., Roopenian D.C., et al. Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity 2004; 20:769-783 (Pubitemid 38757446)
25. Yoshida M., Kobayashi K., Kuo T.T., Bry L., Glickman J.N., Claypool S.M., et al. Neonatal Fc receptor for IgG regulates mucosal immune responses to luminal bacteria. J Clin Invest 2006; 116:2142-2151 (Pubitemid 44162323)
26. Bitonti A.J., Dumont J.A. Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway. Adv Drug Deliv Rev 2006; 58:1106-1118 (Pubitemid 44709269)
27. Akilesh S., Huber T.B., Wu H., Wang G., Hartleben B., Kopp J.B., et al. Podocytes use FcRn to clear IgG from the glomerular basement membrane. Proc Natl Acad Sci USA 2008; 105:967-972 (Pubitemid 351282065)
28. Kobayashi N., Suzuki Y., Tsuge T., Okumura K., Ra C., Tomino Y. FcRn-mediated transcytosis of immunoglobulin G in human renal proximal tubular epithelial cells. Am J Physiol Renal Physiol 2002; 282:358-365
29. Sarav M., Wang Y., Hack B.K., Chang A., Jensen M., Bao L., et al. Renal FcRn reclaims albumin but facilitates elimination of IgG. J Am Soc Nephrol 2009; 20:1941-1952
30. Cianga P., Cianga C., Cozma L., Ward E.S., Carasevici E. The MHC class I related Fc receptor, FcRn, is expressed in the epithelial cells of the human mammary gland. Hum Immunol 2003; 64:1152-1159 (Pubitemid 37475276)
31. Nakata K., Kobayashi K., Ishikawa Y., Yamamoto M., Funada Y., Kotani Y., et al. The transfer of maternal antigen-specific IgG regulates the development of allergic airway inflammation early in life in an FcRn-dependent manner. Biochem Biophys Res Commun 2010; 395:238-243
32. Simister N.E. Placental transport of immunoglobulin G. Vaccine 2003; 21:3365-3369 (Pubitemid 36792087)
33. Grubb J.H., Vogler C., Tan Y., Shah G.N., MacRae A.F., Sly W.S. Infused Fc-tagged beta-glucuronidase crosses the placenta and produces clearance of storage in utero in mucopolysaccharidosis VII mice. Proc Natl Acad Sci USA 2008; 105:8375-8380 (Pubitemid 351904763)
34. Maidji E., McDonagh S., Genbacev O., Tabata T., Pereira L. Maternal antibodies enhance or prevent cytomegalovirus infection in the placenta by neonatal Fc receptor-mediated transcytosis. Am J Pathol 2006; 168:1210-1226
35. Vidarsson G., Stemerding A.M., Stapleton N.M., Spliethoff S.E., Janssen H., Rebers F.E., et al. FcRn: An IgG receptor on phagocytes with a novel role in phagocytosis. Blood 2006; 108:3573-3579
36. Montoyo H.P., Vaccaro C., Hafner M., Ober R.J., Mueller W., Ward E.S. Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice. Proc Natl Acad Sci USA 2009; 106:2788-2793
37. Knee R.A., Hickey D.K., Beagley K.W., Jones R.C. Transport of IgG across the Blood-Luminal Barrier of the Male Reproductive Tract of the Rat and the Effect of Estradiol Administration on Reabsorption of Fluid and IgG by the Epididymal Ducts. Biol Reprod 2005; 73:688-694 (Pubitemid 41356127)
38. Li N., Zhao M., Hilario-Vargas J., Prisayanh P., Warren S., Diaz L.A., et al. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest 2005; 115:3440-3450 (Pubitemid 43121832)
39. Ye L., Zeng R., Bai Y., Roopenian D.C., Zhu X. Efficient mucosal vaccination mediated by the neonatal Fc receptor. Nat Biotechnol 2011; 29:158-163
40. Kim J., Bronson C.L., Hayton W.L., Radmacher M.D., Roopenian D.C., Robinson J.M., et al. Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces. Am J Physiol Gastrointest Liver Physiol 2005.
41. Kim H., Robinson S.B., Csaky K.G. FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye. Mol Vis 2009; 15:2803-2812
42. Kim H., Fariss R.N., Zhang C., Robinson S.B., Thill M., Csaky K.G. Mapping of the neonatal Fc receptor in the rodent eye. Invest Ophthalmol Vis Sci 2008; 49:2025-2029
43. Garg A., Balthasar J.P. Investigation of the influence of FcRn on the distribution of IgG to the brain. Aaps J 2009; 11:553-557
44. Cianga P., Cianga C., Plamadeala P., Branisteanu D., Carasevici E. The neonatal Fc receptor (FcRn) expression in the human skin. Virchows Arch 2007; 451:859-860 (Pubitemid 47497939)
45. Dall'Acqua W.F., Woods R.M., Ward E.S., Palaszynski S.R., Patel N.K., Brewah Y.A., et al. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: Biological consequences. J Immunol 2002; 169:5171-5180 (Pubitemid 35217187)
46. Gurbaxani B., Dela Cruz L.L., Chintalacharuvu K., Morrison S.L. Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life. Mol Immunol 2006; 43:1462-1473 (Pubitemid 43356386)
47. Wang W., Lu P., Fang Y., Hamuro L., Pittman T., Carr B., et al. Monoclonal Antibodies with Identical Fc Sequences Can Bind to FcRn Differentially with Pharmacokinetic Consequences. Drug Metab Dispos 2011.
48. Dall'Acqua W.F., Kiener P.A., Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 2006; 281:23514-23524 (Pubitemid 44274126)
49. Oganesyan V., Damschroder M.M., Woods R.M., Cook K.E., Wu H., Dall'acqua W.F. Structural characterization of a human Fc fragment engineered for extended serum half-life. Mol Immunol 2009; 46:1750-1755
50. Hinton P.R., Johlfs M.G., Xiong J.M., Hanestad K., Ong K.C., Bullock C., et al. Engineered human IgG antibodies with longer serum half-lives in primates. J Biol Chem 2004; 279:6213-6216 (Pubitemid 38248752)
51. Hinton P.R., Xiong J.M., Johlfs M.G., Tang M.T., Keller S., Tsurushita N. An engineered human IgG1 antibody with longer serum half-life. J Immunol 2006; 176:346-356 (Pubitemid 43023280)
52. Datta-Mannan A., Witcher D.R., Tang Y., Watkins J., Wroblewski V.J. Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor. J Biol Chem 2007; 282:1709-1717 (Pubitemid 47076691)
53. Datta-Mannan A., Witcher D.R., Tang Y., Watkins J., Jiang W., Wroblewski V.J. Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: Relationship to pharmacokinetics in mice and primates. Drug Metab Dispos 2007; 35:86-94. (Pubitemid 46036480)
54. Yeung Y.A., Leabman M.K., Marvin J.S., Qiu J., Adams C.W., Lien S., et al. Engineering human IgG1 affinity to human neonatal Fc receptor: Impact of affinity improvement on pharmacokinetics in primates. J Immunol 2009; 182:7663-7671
55. Deng R., Loyet K.M., Lien S., Iyer S., DeForge L.E., Theil F.P., et al. Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. Drug Metab Dispos 38:600-605
56. Shields R.L., Namenuk A.K., Hong K., Meng Y.G., Rae J., Briggs J., et al. High resolution mapping of the binding site on human IgG1 for Fcgamma RI, Fcgamma RII, Fcgamma RIII and FcRn and design of IgG1 variants with improved binding to the Fcgamma R. J Biol Chem 2001; 276:6591-6604
57. Petkova S.B., Akilesh S., Sproule T.J., Christianson G.J., Al Khabbaz H., Brown A.C., et al. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: Potential application in humorally mediated autoimmune disease. Int Immunol 2006; 18:1759-1769 (Pubitemid 44884038)
58. Zalevsky J., Chamberlain A.K., Horton H.M., Karki S., Leung I.W., Sproule T.J., et al. Enhanced antibody halflife improves in vivo activity. Nat Biotechnol 2010; 28:157-159
59. Suzuki T., Ishii-Watabe A., Tada M., Kobayashi T., Kanayasu-Toyoda T., Kawanishi T., et al. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: A comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol 184:1968-1976
60. Pan H., Chen K., Chu L., Kinderman F., Apostol I., Huang G. Methionine oxidation in human IgG2 Fc decreases binding affinities to protein A and FcRn. Protein Sci 2009; 18:424-433
61. Wang W., Vlasak J., Li Y., Pristatsky P., Fang Y., Pittman T., et al. Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies. Mol Immunol 48:860-866
62. Bitonti A.J., Dumont J.A., Low S.C., Peters R.T., Kropp K.E., Palombella V.J., et al. Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc Natl Acad Sci USA 2004; 101:9763-9768 (Pubitemid 38869310)
63. Dumont J.A., Low S.C., Peters R.T., Bitonti A.J. Monomeric Fc fusions: Impact on pharmacokinetic and biological activity of protein therapeutics. BioDrugs 2006; 20:151-160 (Pubitemid 43845335)
64. Peters R.T., Low S.C., Kamphaus G.D., Dumont J.A., Amari J.V., Lu Q., et al. Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood 2010; 115:2057-2064
65. Stork R., Campigna E., Robert B., Muller D., Kontermann R.E. Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives. J Biol Chem 2009; 284:25612-25619
66. Dennis M.S., Jin H., Dugger D., Yang R., McFarland L., Ogasawara A., et al. Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Cancer Res 2007; 67:254-261 (Pubitemid 46142782)
67. Nguyen A., Reyes A.E., 2nd, Zhang M., McDonald P., Wong W.L., Damico L.A., et al. The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of affinity for albumin. Protein Eng Des Sel 2006; 19:291-297 (Pubitemid 43999639)
68. Liu L., Garcia A.M., Santoro H., Zhang Y., McDonnell K., Dumont J., et al. Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade. J Immunol 2007; 178:5390-5398 (Pubitemid 46595326)
69. Vaccaro C., Zhou J., Ober R.J., Ward E.S. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol 2005; 23:1283-1288 (Pubitemid 41486856)
70. Mezo A.R., Sridhar V., Badger J., Sakorafas P., Nienaber V. X-ray Crystal Structures of Monomeric and Dimeric Peptide Inhibitors in Complex with the Human Neonatal Fc Receptor, FcRn. J Biol Chem 2010; 285:27694-27701
71. Mezo A.R., McDonnell K.A., Hehir C.A., Low S.C., Palombella V.J., Stattel J.M., et al. Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn. Proc Natl Acad Sci USA 2008; 105:2337-2342 (Pubitemid 351520514)
72. Dumont J.A., Bitonti A.J., Clark D., Evans S., Pickford M., Newman S.P. Delivery of an Erythropoietin-Fc Fusion Protein by Inhalation in Humans through an Immunoglobulin Transport Pathway. J Aerosol Med 2005; 18:294-303. (Pubitemid 41395731)
73. Low S.C., Nunes S.L., Bitonti A.J., Dumont J.A. Oral and pulmonary delivery of FSH-Fc fusion proteins via neonatal Fc receptor-mediated transcytosis. Hum Reprod 2005; 20:1805-1813 (Pubitemid 40932360)
74. Roopenian D.C., Christianson G.J., Sproule T.J. Human FcRn transgenic mice for pharmacokinetic evaluation of therapeutic antibodies. Methods Mol Biol 2010; 602:93-104.
75. Cervenak J., Kacskovics I. The neonatal Fc receptor plays a crucial role in the metabolism of IgG in livestock animals. Vet Immunol Immunopathol 2009; 128:171-177
76. Lu W., Zhao Z., Zhao Y., Yu S., Zhao Y., Fan B., et al. Overexpression of the bovine FcRn in the mammary gland results in increased IgG levels in both milk and serum of transgenic mice. Immunology 2007; 122:401-408 (Pubitemid 47556477)
77. Vegh A., Cervenak J., Jankovics I., Kacskovics I. FcRn overexpression in mice results in potent humoral response against weakly immunogenic antigen. MAbs 3:173-80.
78. Cervenak J., Bender B., Schneider Z., Magna M., Carstea B.V., Liliom K., et al. Neonatal FcR overexpression boosts humoral immune response in transgenic mice. J Immunol 2011; 186:959-968
79. Dickinson B.L., Badizadegan K., Wu Z., Ahouse J.C., Zhu X., Simister N.E., et al. Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. J Clin Invest 1999; 104:903-911 (Pubitemid 29536340)
80. DeLano W.L., Ultsch M.H., De Vos A.M., Wells J.A. Convergent solutions to binding at a protein-protein interface. Science 2000; 287:1279-1283 (Pubitemid 30112152)